Journal of translational medicine · 2026
MTHFD2: a promising metabolic checkpoint for diseases.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xiang, Ou Renhao, Xu Yana, Zheng Guowan, Xu Haifeng, Luo Ying, Chen Yunzhao, Ren Xinxin
Аннотация
BACKGROUND: MTHFD2, a critical enzyme in one-carbon metabolism, regulates cellular growth, redox balance, and energy homeostasis. Aberrant MTHFD2 expression has been implicated in the pathogenesis and progression of various diseases. MTHFD2 is a promising therapeutic target, however, its roles in diseases and upstream and downstream regulatory mechanisms have not been clarified.
METHODS: This study reviewed literature from databases such as PubMed and Google Scholar, using keywords "MTHFD2", aiming to summarize current research on the functions and mechanisms of MTHFD2 on diseases and provide theoretical support for future investigation of related therapeutic strategies.
RESULTS: High expression of MTHFD2 promotes cancer progression and MTHFD2 can be used as a sensitization target in cancer treatment. MTHFD2 influences tumor microenvironment through disturbing immune cell infiltration and immune checkpoints expression. Aberrant MTHFD2 expression can also participate in other diseases. Consequently, a range of MTHFD2 inhibitors has been developed, advancing to both preclinical and clinical evaluations.
CONCLUSIONS: This review examines the multifaceted roles of MTHFD2 in cancer biology and other pathological conditions, describing its influence on the tumor microenvironment and relevance in immunotherapeutic applications. Structural strategies for MTHFD2 inhibitor development are explored, alongside challenges and opportunities for leveraging MTHFD2 as a diagnostic, therapeutic, and prognostic target in disease management.
METHODS: This study reviewed literature from databases such as PubMed and Google Scholar, using keywords "MTHFD2", aiming to summarize current research on the functions and mechanisms of MTHFD2 on diseases and provide theoretical support for future investigation of related therapeutic strategies.
RESULTS: High expression of MTHFD2 promotes cancer progression and MTHFD2 can be used as a sensitization target in cancer treatment. MTHFD2 influences tumor microenvironment through disturbing immune cell infiltration and immune checkpoints expression. Aberrant MTHFD2 expression can also participate in other diseases. Consequently, a range of MTHFD2 inhibitors has been developed, advancing to both preclinical and clinical evaluations.
CONCLUSIONS: This review examines the multifaceted roles of MTHFD2 in cancer biology and other pathological conditions, describing its influence on the tumor microenvironment and relevance in immunotherapeutic applications. Structural strategies for MTHFD2 inhibitor development are explored, alongside challenges and opportunities for leveraging MTHFD2 as a diagnostic, therapeutic, and prognostic target in disease management.